In this Review, Beringer and colleagues highlight how future strategies for developing immunotherapies using γδT cells and their receptors will depend on creating intentional imbalances between activating and inhibitory receptors through the genetic engineering of γδT cell-inspired biologics and cellular therapies.
- Dennis X. Beringer
- Trudy Straetemans
- Jürgen Kuball
